Melbourne, Australia, 11 September 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is proud to announce that it has been named ‘Most Promising iPSC Therapy Pipeline in APAC’ in the Asia Pacific Cell & Gene Therapy Excellence Awards 2025 (APCGTEA 2025). [Read more…]
What is Regenerative Medicine?
What is regenerative medicine? Put simply, regenerative medicine is the process of replacing or repairing human genes, cells, tissues or organs in order to restore healthy function. It is the processing of working with the human body to assist it to heal itself. In that sense, it is about working “with” biology, instead of “against” or “separate from” it. [Read more…]
Can We Extend the Human Lifespan With Regenerative Medicine?
Regenerative medicine is a fascinating topic, because it requires you to ask yourself: Would you want to live to be 200 years old? A scientist from Stanford University thinks that it’s possible – so much so that he has placed a bet that there is someone alive today who will live to be 200 years old.
Over recent decades, modern scientific developments have led to a dramatic increase in human lifespan. But how much further can we go? Does regenerative medicine have the power to enable us all to live for many more years?
Let’s dive into this fascinating topic and find out more about regenerative medicine. How could it extend human life into the future? [Read more…]
Market Forces Affecting the Cord Blood and Cord Tissue Industry
Recently released, the “Global Cord Blood & Tissue Banking Industry Report – Market Size, Segmentation, and Forecasts” explores clinical trial market data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue. Within this rapidly evolving marketplace, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.
Because the global cord blood banking industry has matured substantially over the past few years, new market forces have created both serious threats and novel opportunities. [Read more…]
Shineco Establishes Biological Cell Digital Division to Integrate iPSC Technology Assets with Blockchain Technology
BEIJING, Aug. 13, 2025 — Shineco Inc. (NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, announced the establishment of a Biological Cell Digital Business Division (the “Division”), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new architecture of blockchain-based cell assets, Shineco aims to build a vertical ecosystem within the biological cell sector, accelerate the global distribution of biological cell products and boost global sales. [Read more…]
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 202
- Next Page »